Who are MB-102 OMID's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): [68Ga]Ga-PentixaFor, TBI-1301, CHS-1420, mini CYVE, without 3 maintenance courses, HP-802-247, MB-102 DMID.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mb-102-omid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

MB-102 OMID — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MB-102 OMID (MB-102 OMID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47 inhibitor. Area: Oncology.

phase 3 CD47 inhibitor CD47 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MB-102 OMID (MB-102 OMID) — Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. MB-102 OMID is a monoclonal antibody targeting CD47.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MB-102 OMID TARGET	MB-102 OMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	CD47 inhibitor	CD47
[68Ga]Ga-PentixaFor	[68Ga]Ga-PentixaFor	Nantes University Hospital	phase 3	Radiopharmaceutical	CD47
TBI-1301	TBI-1301	Takara Bio Inc.	phase 3	CD47 antibody	CD47
CHS-1420	CHS-1420	Coherus Oncology, Inc.	phase 3	Bispecific antibody	CD47 and CD40
mini CYVE, without 3 maintenance courses	mini CYVE, without 3 maintenance courses	Gustave Roussy, Cancer Campus, Grand Paris	phase 3	CD47/SIRPα inhibitor	CD47
HP-802-247	HP-802-247	Healthpoint	phase 3	CD47 antibody	CD47
MB-102 DMID	MB-102 DMID	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	phase 3	monoclonal antibody	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47 inhibitor class)

Addrenex Pharmaceuticals, Inc. · 1 drug in this class
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 1 drug in this class
Q32 Bio Inc. · 1 drug in this class
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MB-102 OMID — Competitive Intelligence Brief. https://druglandscape.com/ci/mb-102-omid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing